Nicholas A. Vitanza
0000-0002-3966-4985
Publication & Citation Trends
Publications
0 total
CTIM-38. PIONEERING QUAD-TARGETING CAR T CELL THERAPY IN PEDIATRIC CNS TUMORS – ANALYSIS FROM THE FIRST-IN-HUMAN PHASE 1 TRIAL BRAINCHILD-04
Cited by 0
Semantic Scholar
DMG-16. Integrative proteogenomic analysis for improved therapeutic decision-making in diffuse midline glioma
Cited by 0
Semantic Scholar
DMG-30. ONC201 induces immune-tumor surveillance and alters the tumor immune microenvironment of diffuse midline glioma models
Cited by 0
Semantic Scholar
DMG-01. Protein changes in CSF as biomarkers of CAR activity and disease response in patients with DIPG treated on the BrainChild03 trial
Cited by 0
Semantic Scholar
DMG-59. Preclinical efficacy of JAK2/IRAK1/ACVR1 inhibitor pacritinib against diffuse midline glioma (DMG)
Cited by 0
Semantic Scholar
CTIM-03. PROTEIN CHANGES IN SERIAL CSF SAMPLES REFLECT CAR ACTIVITY, TOXICITY AND DISEASE RESPONSE IN PATIENTS WITH DIPG TREATED ON THE BRAINCHILD03 TRIAL
Cited by 0
Semantic Scholar
DMG-65. The Diffuse Intrinsic Glioma (DIPG) and Diffuse Midline Glioma (DMG) National Brain Tumor Board: Review of Resource Implementation and Utilization
Cited by 0
Semantic Scholar
DDDR-38. Leveraging the immunomodulatory effects of dordaviprone (ONC201) to induce long-term survival response in diffuse midline glioma patients and models
Cited by 0
Semantic Scholar
Research Topics
Glioma Diagnosis and Treatment
(135)
CAR-T cell therapy research
(56)
Neuroblastoma Research and Treatments
(36)
Protein Degradation and Inhibitors
(16)
Cancer, Hypoxia, and Metabolism
(15)
Affiliations
Center for Infectious Disease Research
Seattle Children's Hospital
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa
Lucile Packard Children's Hospital
Palo Alto University